Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address:Issue Date
2020
Metadata
Show full item recordAbstract
Radiomics has become a popular image analysis method in the last few years. Its key hypothesis is that medical images harbor biological, prognostic and predictive information that is not revealed upon visual inspection. In contrast to previous work with a priori defined imaging biomarkers, radiomics instead calculates image features at scale and uses statistical methods to identify those most strongly associated to outcome. This builds on years of research into computer aided diagnosis and pattern recognition. While the potential of radiomics to aid personalized medicine is widely recognized, several technical limitations exist which hinder biomarker translation. Aspects of the radiomic workflow lack repeatability or reproducibility under particular circumstances, which is a key requirement for the translation of imaging biomarkers into clinical practice. One of the most commonly studied uses of radiomics is for personalized medicine applications in Non-Small Cell Lung Cancer (NSCLC). In this review, we summarize reported methodological limitations in CT based radiomic analyses together with suggested solutions. We then evaluate the current NSCLC radiomics literature to assess the risk associated with accepting the published conclusions with respect to these limitations. We review different complementary scoring systems and initiatives that can be used to critically appraise data from radiomics studies. Wider awareness should improve the quality of ongoing and future radiomics studies and advance their potential as clinically relevant biomarkers for personalized medicine in patients with NSCLC. Keywords: Imaging biomarkers; Lung cancer; Personalized medicine; Radiomics.Citation
Fornacon-Wood I, Faivre-Finn C, O'Connor JPB, Price GJ. Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype. Lung Cancer. 2020;146:197-208.Journal
Lung CancerDOI
10.1016/j.lungcan.2020.05.028PubMed ID
32563015Additional Links
https://dx.doi.org/10.1016/j.lungcan.2020.05.028Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2020.05.028
Scopus Count
Collections
Related articles
- Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives.
- Authors: Chetan MR, Gleeson FV
- Issue date: 2021 Feb
- Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer.
- Authors: Shi L, He Y, Yuan Z, Benedict S, Valicenti R, Qiu J, Rong Y
- Issue date: 2018 Jan 1
- Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis.
- Authors: Chen Q, Zhang L, Mo X, You J, Chen L, Fang J, Wang F, Jin Z, Zhang B, Zhang S
- Issue date: 2021 Dec
- Radiomics features as predictive and prognostic biomarkers in NSCLC.
- Authors: Bortolotto C, Lancia A, Stelitano C, Montesano M, Merizzoli E, Agustoni F, Stella G, Preda L, Filippi AR
- Issue date: 2021 Mar
- Homology-based radiomic features for prediction of the prognosis of lung cancer based on CT-based radiomics.
- Authors: Kadoya N, Tanaka S, Kajikawa T, Tanabe S, Abe K, Nakajima Y, Yamamoto T, Takahashi N, Takeda K, Dobashi S, Takeda K, Nakane K, Jingu K
- Issue date: 2020 Jun